Stefan Hauser1, Annette Kaminski2, Isabella Syring2, Stefan Holdenrieder3, Klaus-Peter Dieckmann4, Stefan C Muller2, Jorg Ellinger2. 1. Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany stefan.hauser@ukbonn.de. 2. Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany. 3. Universitätsklinikum Bonn, Institut für Klinische Chemie und Klinische Pharmakologie, Bonn, Germany. 4. Albertinen Krankenhaus, Klinik für Urologie, Hamburg, Germany.
Abstract
BACKGROUND/AIM: FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers. MATERIALS AND METHODS: Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men. RESULTS: Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters. CONCLUSION: FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients. Copyright
BACKGROUND/AIM: FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancerpatients in earlier studies. Our study was designed to validate these potential novel tumor markers. MATERIALS AND METHODS: Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancerpatients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men. RESULTS: Serum FGF-2, HGF and PTN levels did not differ in cancerpatients and healthy males within the screening cohort, whereas MIF was significantly increased among cancerpatients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters. CONCLUSION:FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancerpatients. Copyright
Authors: U Latza; H D Foss; H Dürkop; F Eitelbach; K P Dieckmann; V Loy; M Unger; G Pizzolo; H Stein Journal: Am J Pathol Date: 1995-02 Impact factor: 4.307
Authors: Mahmoud M Kamel; Mohamed F Saad; Amal A Mahmoud; Awatief A Edries; Ahmed S Abdel-Moneim Journal: Microb Pathog Date: 2014-10-22 Impact factor: 3.738
Authors: Jörg Ellinger; Peter Albers; Frank G Perabo; Stefan C Müller; Alexander von Ruecker; Patrick J Bastian Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: A Aigner; P Brachmann; J Beyer; R Jäger; D Raulais; M Vigny; A Neubauer; A Heidenreich; S Weinknecht; F Czubayko; G Zugmaier Journal: Ann Oncol Date: 2003-10 Impact factor: 32.976
Authors: Jörg Ellinger; Volker Wittkamp; Peter Albers; Frank G E Perabo; Stefan C Mueller; Alexander von Ruecker; Patrick J Bastian Journal: J Urol Date: 2008-11-17 Impact factor: 7.450
Authors: Brieze R Keeley; Farhad Islami; Akram Pourshams; Hossein Poustchi; Jamie S Pak; Paul Brennan; Hooman Khademi; Eric M Genden; Christian C Abnet; Sanford M Dawsey; Paolo Boffetta; Reza Malekzadeh; Andrew G Sikora Journal: Cancer Sci Date: 2014-09-03 Impact factor: 6.716
Authors: Mariana Barbosa DE Souza; Otávio Alberto Curioni; Jossi Ledo Kanda; Marcos Brasilino DE Carvalho Journal: Oncol Lett Date: 2014-09-09 Impact factor: 2.967